GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Cyclically Adjusted Price-to-FCF

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tribute Pharmaceuticals Canada Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada Cyclically Adjusted Price-to-FCF Chart

Tribute Pharmaceuticals Canada Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tribute Pharmaceuticals Canada Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF falls into.



Tribute Pharmaceuticals Canada Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Tribute Pharmaceuticals Canada's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2015 is calculated as:

For example, Tribute Pharmaceuticals Canada's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2015 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=-0.004/100.4214*100.4214
=-0.004

Current CPI (Sep. 2015) = 100.4214.

Tribute Pharmaceuticals Canada Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200512 -0.013 85.015 -0.015
200603 -0.019 85.805 -0.022
200606 -0.013 86.516 -0.015
200609 -0.008 86.279 -0.009
200612 0.086 86.437 0.100
200703 -0.014 87.780 -0.016
200706 -0.002 88.412 -0.002
200709 0.004 88.412 0.005
200712 0.003 88.491 0.003
200803 -0.009 88.965 -0.010
200806 -0.008 91.177 -0.009
200809 -0.007 91.414 -0.008
200812 -0.015 89.518 -0.017
200903 0.009 90.071 0.010
200906 -0.017 90.940 -0.019
200909 0.002 90.624 0.002
200912 0.017 90.703 0.019
201003 -0.022 91.335 -0.024
201006 -0.003 91.809 -0.003
201009 0.061 92.362 0.066
201012 0.005 92.836 0.005
201103 -0.025 94.338 -0.027
201106 -0.010 94.654 -0.011
201109 0.003 95.286 0.003
201112 -0.008 94.970 -0.008
201203 -0.032 96.155 -0.033
201206 -0.021 96.076 -0.022
201209 -0.017 96.392 -0.018
201212 0.008 95.760 0.008
201303 -0.083 97.103 -0.086
201306 -0.010 97.182 -0.010
201309 -0.024 97.419 -0.025
201312 0.004 96.945 0.004
201403 -0.036 98.604 -0.037
201406 -0.009 99.473 -0.009
201409 -0.014 99.394 -0.014
201412 -0.369 98.367 -0.377
201503 -0.022 99.789 -0.022
201506 -0.059 100.500 -0.059
201509 -0.004 100.421 -0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tribute Pharmaceuticals Canada  (OTCPK:TBUFF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Tribute Pharmaceuticals Canada Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines